Navigation Links
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Date:1/30/2008

ll is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media and Investor Contact:

David Schull or Wendy Lau

Russo Partners

212-845-4271

david.schull@russopartnersllc.com

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
7. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
8. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
9. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
10. BioCryst Updates Peramivir Clinical Development Plan
11. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2008).../- Simcere,Pharmaceutical G...plier of,branded generic pharmaceuticals and manuf...t Endu (also known as Endostar) in China,announce...udy., At the request of the SFDA, Simcere initiat...he safety and therapeutic efficacy of Endu, a modi...
(Date:9/3/2008)...sults from chronically infected Hepatitis C,patien...ned earlier in 2008, - Study is the first to sho... antiviral effect of therapeutic Hepatitis C vacci... move into a second generation, vaccine formulate... TLR activation, VI...
(Date:9/3/2008)...NEVA, Sept. 3 /- Artelis SA and,Selex... monoclonal antibody,production with the achieveme...ter. This record level was accomplished by applyin...erformance stable Selexis CHO,production cell line...at,Selexis SA using their proprietary Selexis Gene...
(Date:9/3/2008)...Multaq(R) (dronedarone) decreased the risk of,stro...trial flutter already adequately trea... Sept. 3 /- The results of ...udy were presented today at,the clinical trial upd...congress 2008, in Munich, Germany. Previous result...
Breaking Medicine Technology:Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Nosefrida Nasal Aspirator A Parents Alternative to Medicines on the Verge of FDA Ban 2978 1Nosefrida Nasal Aspirator A Parents Alternative to Medicines on the Verge of FDA Ban 2978 2Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai 2975 1Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai 2975 2Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2973 1Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2973 2HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 1HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 2HealthShares 28TM 29 Announces Change to the HealthShares 28TM 29 Cardio Devices Index 2969 3
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
... craze in the American Society, not only among wom...rch, men under pressure to have a good physique ma...eroids, and an unhealthy preoccupation with weight...zed, muscular men in the media and feel their own ...
...re the best time for one to undergo an operation./... in the US has analysed the outcomes of over 90,00...ve concluded that mornings are the best time to ha...at more complications occur when performed in the ...
...it will be publishing a peer-reviewed clinical ove...g is. RESPeRATE, a over-the-counter// therapeutic ...ption to treat hypertension, the study says. The ...cine Journal (http://www.medscape.com/viewarticle/...
... though they do not develop zits, the do have oily...e to differentiate the cells// in the sebaceous gl...esearch examines how a sebaceous gland is formed. ...ust 11 issue of Cell, Elaine Fuchs, a Howard Hughe...
Other Medicine News:Health News:Men Take to Unhealthy Practices to be More Muscular 2Health News:Surgeries Performed In The Morning Have Less Post-Op Complications 2Health News:New Treatment Mooted For Blood Pressure 2Health News:'Blimp1' Gene Linked To Oily Skin 2
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump.
...inimally invasive, highly effective surgical alter...nence. GYNECARE TVT is positioned close to the hig...VT provides tension-free support of the urethra in...mately 20 to 30 minutes, with minimal tissue disse...
SUR-FIT® AutoLock® Urostomy Pouch with Accuseal® Tap
New Image Urostomy Pouch, Ultra-Clear
Medicine Products: